Literature DB >> 23549732

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.

Johannes L Blaauwgeers1, Ingrid Kappers, Houke M Klomp, José S Belderbos, Lea M Dijksman, Egbert F Smit, Pieter E Postmus, Marinus A Paul, Jan W Oosterhuis, Koen J Hartemink, Cornelis G Vos, Jacobus A Burgers, Max Dahele, Erik C Phernambucq, Birgit I Witte, Erik Thunnissen.   

Abstract

The objective was to define the relationship between histopathological changes after pre-operative chemo-radiotherapy (CRT) and clinical outcome following tri-modality therapy in patients with superior sulcus tumours. A retrospective analysis of tumour material was performed in a series of 46 patients who received tri-modality therapy between 1997 and 2007. Median follow-up was 34 months (5-154). Pathological complete response (pCR) was present in 20/46 tumours (43 %). The most common RECIST score after CRT in patients with pCR was a partial response (PR; 10/17, three unknown), whereas in patients without a pCR, stable disease was the most common (22/26) (p = 0.002). In 26 specimens with residual tumour, this was mainly located in the periphery of the lesion rather than the centre (Spearman's correlation = 0.67, p < 0.001). Prognosis was significantly better after a pCR compared to residual tumour (70 % 5-year overall survival vs. 20 %; p = 0.001) and in patients with fewer than 10 % vital tumour cells as compared to those with >10 % (65 % 5-year overall survival vs. 18 %; p < 0.001). A low mitotic count was associated with a longer disease-free survival (p = 0.02). Complete pathological response and the presence of fewer than 10 % vital tumour cells after pre-operative CRT are both associated with a more favourable prognosis. A modification of the pathological staging system after radiotherapy, incorporating the percentage of vital tumour cells, is proposed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549732     DOI: 10.1007/s00428-013-1404-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

Review 1.  Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)?

Authors:  C Peedell; J Dunning; A Bapusamy
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-03-26       Impact factor: 4.126

2.  Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.

Authors:  Shin-Ichi Takeda; Hajime Maeda; Tatsuya Okada; Toshihiko Yamaguchi; Masaru Nakagawa; Soichiro Yokota; Noriyoshi Sawabata; Mitsunori Ohta
Journal:  Eur J Cardiothorac Surg       Date:  2006-05-26       Impact factor: 4.191

Review 3.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

4.  Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.

Authors:  Ingrid Kappers; Johanna W van Sandick; Jacques A Burgers; José S A Belderbos; Michel W Wouters; Nico van Zandwijk; Houke M Klomp
Journal:  Eur J Cardiothorac Surg       Date:  2009-08-21       Impact factor: 4.191

5.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

Review 6.  The revised TNM staging system for lung cancer.

Authors:  Ramon Rami-Porta; John J Crowley; Peter Goldstraw
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 1.520

7.  Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.

Authors:  Nicolas Pourel; Nicola Santelmo; Nidal Naafa; Antoine Serre; Werner Hilgers; Laurent Mineur; Nicolas Molinari; François Reboul
Journal:  Eur J Cardiothorac Surg       Date:  2008-03-25       Impact factor: 4.191

8.  Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.

Authors:  E Bollschweiler; R Metzger; U Drebber; S Baldus; D Vallböhmer; M Kocher; A H Hölscher
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

9.  Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.

Authors:  Hale B Caglar; Elizabeth H Baldini; Megan Othus; Michael S Rabin; Raphael Bueno; David J Sugarbaker; Steven J Mentzer; Pasi A Jänne; Bruce E Johnson; Aaron M Allen
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

10.  A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.

Authors:  Yuki Yamane; Genichiro Ishii; Koichi Goto; Motohiro Kojima; Masayuki Nakao; Yoshihisa Shimada; Yutaka Nishiwaki; Kanji Nagai; Hirotsugu Kohrogi; Atsushi Ochiai
Journal:  J Thorac Oncol       Date:  2010-01       Impact factor: 15.609

View more
  3 in total

Review 1.  [Therapy-induced tumor regression and regression grading in lung cancer].

Authors:  K Junker
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.

Authors:  Sijia Ren; Anyi Xu; Yilian Lin; D Ross Camidge; Massimo Di Maio; Raffaele Califano; Toyoaki Hida; Antonio Rossi; Nicolas Guibert; Chengchu Zhu; Jianfei Shen
Journal:  Transl Lung Cancer Res       Date:  2021-07

Review 3.  Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.

Authors:  Anjali Saqi; Kevin O Leslie; Andre L Moreira; Sylvie Lantuejoul; Catherine Ann Shu; Naiyer A Rizvi; Joshua R Sonett; Kosei Tajima; Shawn W Sun; Barbara J Gitlitz; Thomas V Colby
Journal:  JTO Clin Res Rep       Date:  2022-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.